Engineered immune cells take on virus in transplant patients
NCT ID NCT06119256
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether specially engineered immune cells (EBV-TCR-T cells) can safely control Epstein-Barr virus infections in people who have had a stem cell transplant. About 12 participants will receive one to three infusions of donor-derived cells. The main goal is to check for side effects and see if the virus levels drop.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EBV-TCR-T cells (immune cells engineered to target the Epstein-Barr virus)
- What this could lead to
- If it works, this could point toward a treatment for EBV infections after stem cell transplants, reducing complications.
- What could go wrong
- This is a very early phase 1 trial with only 12 participants, so it may not show clear benefit or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV INFECTION AFTER ALLOGENIC HSCT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.